The court, however, permitted Sun Pharma to manufacture and export semaglutide to non-patent countries, extending the same relief it granted Dr. Reddy’s Laboratories in a similar dispute earlier this ...
MBX Biosciences, Inc. is rated a Buy, driven by canvuparatide's once-weekly dosing advantage in hypoparathyroidism. Learn ...
Novo Nordisk A/S (NYSE:NVO) is among the cheap healthcare stocks to buy heading into 2026. On December 5, Kerry Holford, an analyst at Berenberg Bank, reaffirmed the ‘Buy’ rating on Novo Nordisk A/S ...
Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.
The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...
The Delhi High Court has allowed Sun Pharma to manufacture and export semaglutide-based drugs to countries where Novo Nordisk ...
James Corden admitted he ditched Ozempic last year after it failed to curb his eating habits - but his lookalike sister, Ruth ...
The order followed the company’s assurance that it would not market any anti-obesity products in India until the patent lapses. The court had granted similar relief to Dr Reddy’s Laboratories earlier ...
Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP-1 drugs, like Ozempic. While injectable GLP-1s work by ...
Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...
A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight ...
About one in eight adults say they are taking a GLP-1 receptor agonist as a treatment for obesity, diabetes or another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback